Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
Charles E. Jobson filed an amended Schedule 13G reporting beneficial ownership of 1,075,994 shares of JOINT Corp common stock (CUSIP 47973J102), representing 7.01% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over all reported shares, and no shared voting or dispositive arrangements are reported. The document lists JOINT Corp's principal executive office in Scottsdale, Arizona, and Mr. Jobson's residence in Wellesley, Massachusetts. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and certification language attests to the accuracy of the statement.
Christopher M. Grandpre, a director of The Joint Corp. (JYNT), reported two open-market purchases of the issuer's common stock in mid-August 2025. The filing shows a purchase of 14,388 shares on 08/15/2025 at a weighted average price of $10.8793 and a subsequent purchase of 10,000 shares on 08/18/2025 at a weighted average price of $10.6978. Following these transactions he beneficially owned 29,383 shares as a direct owner. The filing was submitted under a Form 4 and signed by an attorney-in-fact on 08/19/2025. No derivative transactions, dispositions, or additional contextual details about the purpose of the purchases are provided in this document.
Schedule 13G filing overview – The Joint Corp. (JYNT)
On 10 July 2025, Skylands Capital, LLC, a Wisconsin-based investment adviser, submitted a Schedule 13G reporting its beneficial ownership in The Joint Corp. common stock. The filing relates to an event dated 30 June 2025.
- Shares owned: 779,295
- % of outstanding class: 5.1%
- Voting power: Sole power to vote and dispose of all reported shares; no shared power
- Filing basis: Rule 13d-1(b) – passive investment by an investment adviser (IA)
- Intent statement: Securities acquired and held in the ordinary course, not for the purpose of influencing control
The disclosure means Skylands has crossed the 5 % reporting threshold, giving investors fresh insight into institutional ownership dynamics at The Joint Corp. No other entities or group relationships are identified, and there are no indications of activist intent.
Joint (NASDAQ:JYNT) agreed to sell the assets of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $11.07 million, with closing targeted on or before 30 Jun 2025 and customary conditions attached. In return, the company will obtain regional developer rights covering 46 existing franchised clinics and 30 future development sites across Northern California, Utah, Nevada, Washington and Oregon, enlarging its franchise pipeline.
In a separate transaction, the company divested five clinics in Kansas and Missouri to 93 Chiro, LLC. Management positions both deals as part of a strategic shift toward an asset-light, royalty-driven model that increases liquidity, cuts operating costs and accelerates unit growth.